By Jorge Mercado Senior Staff Writer Amgen, riding the wave of its rising stock this year, has been exploring the possible acquisition of Horizon Therapeutics, a $22 billion market cap NASDAQ-traded biotechnology company, Horizon said, naming the other possible bidder as Sanofi. Thousand Oaks-based Amgen, one of the world’s largest independent biopharmaceutical companies with a…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
